Skip to content

Debt-to-equity at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
0.1×0.0×
Opko Health logo
Opko HealthOPK
0.0×
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
0.0×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-1.5×
ALN
Alnylam PharmaceuticalsALNY
0.2×-0.4×
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
0.1×0.0×

Other financials

Income statement

See full
Revenue$293.0K-84.8%
Operating income-$40.8M+1.9%
Net income-$46.3M-15.8%
EPS (diluted)-$0.57-11.8%

Balance sheet

See full
Cash & equivalents$71.5M+7.5%
Total debt$62.7M-22.5%
Total equity-$58.1M-276%
Total assets$244.7M+9.2%

Cash flow

See full
Operating cash flow$17.8M+148%
CapEx$2.0M+17.4%
Free cash flow$15.8M+141%

Valuation

See full
Market cap$1.07B+111%
Enterprise value$1.07B+103%
P/S13.5×-1.3×

Profitability

See full
Operating margin-597.9%-207pp
Net margin-615.3%
FCF margin-441.5%-126pp

Returns & leverage

See full
Return on equity-379.5%
Current ratio0.5×-1.0×

Where this comes from

Calculated from MeiraGTx Holdings plc’s reported figures.

Based on the most recent quarter.

The official record: MeiraGTx Holdings plc’s 10-Q, filed August 14, 2025, on SEC EDGAR. View the filing →

Ask your AI about MeiraGTx Holdings plc's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MeiraGTx Holdings plc's debt-to-equity?
MeiraGTx Holdings plc (MGTX) reported debt-to-equity of 27.2× in Q2 2025.
How has MeiraGTx Holdings plc's debt-to-equity changed year-over-year?
MeiraGTx Holdings plc's debt-to-equity increased by 2385.0% year-over-year, from 1.1× to 27.2×.
What is the long-term trend for MeiraGTx Holdings plc's debt-to-equity?
Over 4 years (2020 to 2024), MeiraGTx Holdings plc's debt-to-equity has grown at a 91.3% compound annual growth rate (CAGR), from 0.1× to 1.3×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.